Morgan Stanley’s TransCode Therapeutics RNAZ Stock Holding History

Morgan Stanley’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-179	Closed	-$2.48K	–	8247
2025 Q1	$2.48K	Buy	179 +168	+1,527%	+$21.5K	﹤0.01%	7134
2024 Q4	$1.02K	Hold	11	–	–	﹤0.01%	7271
2024 Q3	$5.71K	Hold	11	–	–	﹤0.01%	6874
2024 Q2	$10K	Buy	+11	New	+$9.8K	﹤0.01%	6679
2023 Q1	–	Hold	0	–	-$784	–	7813
2022 Q4	–	Hold	0	–	–	–	7505

Other funds holding RNAZ

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SouthState Corp Winter Haven, Florida $2.4B AUM 23.05% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Morgan Stanley's RNAZ Position: Q2 2025 in Review

Morgan Stanley sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 179 shares — an estimated $2.48K sold.

Morgan Stanley first reported a position in RNAZ in Q2 2024 and held it in 4 quarters. The position peaked at $10K in Q2 2024. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

Morgan Stanley reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
Morgan Stanley sold 179 TransCode Therapeutics shares in Q2 2025, an estimated $2.48K.
Morgan Stanley first reported a position in TransCode Therapeutics in Q2 2024 and held it in 4 quarters.
Morgan Stanley's TransCode Therapeutics position peaked at $10K in Q2 2024.
9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.